BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 26385075)

  • 1. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
    Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
    Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we move towards personalised pancreatic cancer therapy?
    Jamieson NB; Chang DK; Grimmond SM; Biankin AV
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
    Lowder CY; Dhir T; Goetz AB; Thomsett HL; Bender J; Tatarian T; Madhavan S; Petricoin EF; Blais E; Lavu H; Winter JM; Posey J; Brody JR; Pishvaian MJ; Yeo CJ
    Surg Oncol; 2020 Jun; 33():118-125. PubMed ID: 32561076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
    Herman JM; Fan KY; Wild AT; Wood LD; Blackford AL; Donehower RC; Hidalgo M; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):458-9. PubMed ID: 24074918
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants.
    Giri B; Sethi V; Dudeja V; Banerjee S; Livingstone A; Saluja A
    Curr Opin Gastroenterol; 2017 Sep; 33(5):404-410. PubMed ID: 28682795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
    Alemi F; Alseidi A; Scott Helton W; Rocha FG
    Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
    [No Abstract]   [Full Text] [Related]  

  • 9. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
    Kawaida H; Fujii H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
    [No Abstract]   [Full Text] [Related]  

  • 12. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
    Chandana S; Mahadevan D
    Expert Rev Mol Med; 2009 Nov; 11():e34. PubMed ID: 19919723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
    Santi I; Brandt A; Hemminki K
    Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
    [No Abstract]   [Full Text] [Related]  

  • 15. [CRITICAL VIEWPOINT ON THE CURRENT APPROACH OF LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA].
    Van Daele D; Martinive P; Loly C; Polus M; Collignon J; Gast P; Louis E; Van Laethem JL
    Rev Med Liege; 2015 Nov; 70(11):540-5. PubMed ID: 26738264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 17. Genomics of pancreatic ductal adenocarcinoma.
    Pilarsky C; Grutzmann R
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
    Philip PA; Mooney M; Jaffe D; Eckhardt G; Moore M; Meropol N; Emens L; O'Reilly E; Korc M; Ellis L; Benedetti J; Rothenberg M; Willett C; Tempero M; Lowy A; Abbruzzese J; Simeone D; Hingorani S; Berlin J; Tepper J
    J Clin Oncol; 2009 Nov; 27(33):5660-9. PubMed ID: 19858397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.